Skip to main content

Table 3 Co-morbidities in Hypopituitary patients

From: Classic cardiovascular risk factors improve in very elderly hypopituitary patients treated on standard hormone replacement in long term follow- up

Comorbidities

 

Age (years)

P- value

Total

(n = 35)

70–74 (%)

(n = 16)

75–79 (%)

(n = 12)

80–99 (%)

(n = 7)

 

Hypertensiona (%)

85.7

93.8

83.3

71.4

0.35

Diabetesb (%)

37.1

43.8

33.3

28.5

0.74

HDL < 40 men/ HDL < 50 women

53.1

64.3

50

33.3

0.42

Hypertrigliceridemia > 150 mg/dL (%)

51.5

57.1

58.3

28.5

0.39

Hypopituitarism (%)

 GH deficiency

65.71

56.2

66.7

85.7

0.39

 Hypogonadism

88.6

87.5

83.3

100

0.53

 Hypothyroidism

82.9

87.5

83.3

71.4

0.64

 Adrenal Insufficiency

25.7

12.5

33.3

42.9

0.23

Multiple Pituitary Hormone Deficiencies (MPHD)

    

0.52

 2 axes

45.7

50

41.7

42.9

 

 3 axes

28.6

37.5

25

14.3

 

 4 axes

20

6.2

25

42.9

 
  1. aMost patients treated by enalapril and valsartan
  2. b Patients treated by diet, metformin and/or glibenclamide